Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is projected to see significant growth in the near future due to the successful launch of a new early cancer detection test and an increase in average selling prices. However, competition and potential funding issues may pose risks to the company's success. Despite this, strong financials and a promising pipeline suggest potential for future growth and success.

Bears say

Caris Life Sciences is a patient-centric, AI TechBio company with a portfolio of precision molecular diagnostic solutions and a strong presence in the precision oncology testing market. However, the recent launch of their first early cancer detection assay, Caris Detect, into the highly competitive $100 billion TAM presents significant risk and uncertainty for the company's financial performance. Additionally, while Caris has a successful track record in commercializing its flagship tissue therapy selection test, there is a risk that the newer blood-based test, Caris Assure, may not achieve similar levels of success. Furthermore, Caris has incurred significant losses since inception and will need to generate significant additional revenue to achieve and sustain profitability. With further uncertainty surrounding regulatory approval and reimbursement for its innovative solutions, as well as potential future legal compliance issues, it is unclear if Caris will be able to achieve long-term profitability.

CAI (CAI) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 9 analysts, CAI (CAI) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.